Literature DB >> 17336419

Worldwide mortality from cirrhosis: an update to 2002.

Cristina Bosetti1, Fabio Levi, Franca Lucchini, Witold A Zatonski, Eva Negri, Carlo La Vecchia.   

Abstract

BACKGROUND/AIMS: Cirrhosis mortality has registered large changes over the last few decades.
METHODS: Age-standardized (world standard) cirrhosis mortality rates per 100,000 were computed for 41 countries worldwide over the period 1980-2002 using data from the WHO mortality database.
RESULTS: In the early 1980s, the highest rates were in Mexico, Chile (around 55/100,000 men and over 14/100,000 women), France, Italy, Portugal, Austria, Hungary and Romania (around 30-35/100,000 men and 10-15/100,000 women). Mortality from cirrhosis has been steadily declining in most countries worldwide since the mid or late 1970s (annual percent change, APC, between -5% and -1.5% in the last decade only for both sexes). In southern Europe, rates in the early 2000s were less than halved compared to earlier decades. In contrast, rates have been rising in Eastern European countries to reach extremely high values in the mid 1990s, and declined only thereafter. In the UK rates were still steadily rising (APC around +7% in men and +3% in women from England and Wales, and +9% in men and +7% in women from Scotland).
CONCLUSIONS: Mortality from cirrhosis shows favourable trends in most countries of the world, following the reduction in alcohol consumption and hepatitis B and C virus infection. The steady upward trends observed over more recent calendar periods in the UK and central and eastern European countries are attributed to the persistent increase in the prevalence of alcohol consumption.

Entities:  

Mesh:

Year:  2007        PMID: 17336419     DOI: 10.1016/j.jhep.2007.01.025

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  51 in total

Review 1.  Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C.

Authors:  Alessio Aghemo; Maria Grazia Rumi; Massimo Colombo
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07-20       Impact factor: 46.802

Review 2.  Impact of etiological treatment on prognosis.

Authors:  Chien-Wei Su; Ying-Ying Yang; Han-Chieh Lin
Journal:  Hepatol Int       Date:  2017-07-12       Impact factor: 6.047

3.  ACE2 Therapy Using Adeno-associated Viral Vector Inhibits Liver Fibrosis in Mice.

Authors:  Kai Y Mak; Ruth Chin; Sharon C Cunningham; Miriam R Habib; Joseph Torresi; Alexandra F Sharland; Ian E Alexander; Peter W Angus; Chandana B Herath
Journal:  Mol Ther       Date:  2015-05-25       Impact factor: 11.454

4.  Hypophosphatemia and recovery of post-hepatectomy liver insufficiency.

Authors:  Julie Hallet; Paul J Karanicolas; Francis S W Zih; Eva Cheng; Julia Wong; Sherif Hanna; Natalie G Coburn; Calvin H L Law
Journal:  Hepatobiliary Surg Nutr       Date:  2016-06       Impact factor: 7.293

5.  Alcoholic liver disease-related mortality in the United States: 1980-2003.

Authors:  Helga Paula; Sumeet K Asrani; Nicholas C Boetticher; Rachel Pedersen; Vijay H Shah; W Ray Kim
Journal:  Am J Gastroenterol       Date:  2010-02-23       Impact factor: 10.864

6.  Hepatitis and liver disease knowledge and preventive practices among health workers in Mexico: a cross-sectional study.

Authors:  Noreen Islam; Yvonne N Flores; Paula Ramirez; Roshan Bastani; Jorge Salmerón
Journal:  Int J Public Health       Date:  2013-10-06       Impact factor: 3.380

7.  Patient knowledge about disease self-management in cirrhosis.

Authors:  Michael L Volk; Natalie Fisher; Robert J Fontana
Journal:  Am J Gastroenterol       Date:  2013-03       Impact factor: 10.864

8.  Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies.

Authors:  Carole L Hart; David S Morrison; G David Batty; Richard J Mitchell; George Davey Smith
Journal:  BMJ       Date:  2010-03-11

9.  Morphological changes of rat astrocytes induced by liver damage but not by manganese chloride exposure.

Authors:  Susana Rivera-Mancía; Sergio Montes; Maricela Méndez-Armenta; Pablo Muriel; Camilo Ríos
Journal:  Metab Brain Dis       Date:  2009-04-08       Impact factor: 3.584

10.  Inhibition of SIRT2 suppresses hepatic fibrosis.

Authors:  Maribel Arteaga; Na Shang; Xianzhong Ding; Sherri Yong; Scott J Cotler; Mitchell F Denning; Takashi Shimamura; Peter Breslin; Bernhard Lüscher; Wei Qiu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-04-28       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.